These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21105879)

  • 41. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.
    Ogawa N; Kanda Y; Matsubara M; Asano Y; Nakagawa M; Sakata-Yanagimoto M; Kandabashi K; Izutsu K; Imai Y; Hangaishi A; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Bone Marrow Transplant; 2004 Mar; 33(5):549-52. PubMed ID: 14716350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation.
    Gota V; Purohit V; Gurjar M; Nayak L; Punatar S; Gokarn A; Bonda A; Bagal B; Vora CS; Patil A; Nookala M; Khattry N
    Cell Transplant; 2020; 29():963689720912925. PubMed ID: 32495641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients.
    Kishi Y; Murashige N; Kami M; Miyakoshi S; Shibagaki Y; Hamaki T; Takaue Y; Taniguchi S;
    Bone Marrow Transplant; 2005 Jun; 35(11):1079-82. PubMed ID: 15806118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
    Knoop C; Vervier I; Thiry P; De Backer M; Kovarik JM; Rousseau A; Marquet P; Estenne M
    Transplantation; 2003 Aug; 76(4):683-8. PubMed ID: 12973109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
    Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.
    Furukawa T; Kurasaki-Ida T; Masuko M; Tsukada N; Okazuka K; Sato N; Yano T; Abe T; Momoi A; Shibasaki Y; Higashimura M; Karimata K; Moriyama M; Kuroha T; Takizawa J; Toba K; Narita M; Fuse I; Takahashi M; Aizawa Y
    Int J Hematol; 2010 Jul; 92(1):144-51. PubMed ID: 20533008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
    Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2003 Oct; 32(8):777-84. PubMed ID: 14520421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.
    Goyal RK; Han K; Wall DA; Pulsipher MA; Bunin N; Grupp SA; Mada SR; Venkataramanan R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):569-75. PubMed ID: 23266742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients.
    Yamazaki R; Mori T; Aisa Y; Kato J; Nakamura Y; Nakazato T; Mihara A; Ikeda Y; Okamoto S
    Transplant Proc; 2009 Jun; 41(5):1831-3. PubMed ID: 19545738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations.
    Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO
    Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients.
    Choi JS; Lee SH; Chung SJ; Yoo KH; Sung KW; Koo HH
    Bone Marrow Transplant; 2006 Jul; 38(1):29-35. PubMed ID: 16715103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.